S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.
about
Disposition of flavonoids via enteric recycling: enzyme stability affects characterization of prunetin glucuronidation across species, organs, and UGT isoformsIdentification of residues that confer sugar selectivity to UDP-glycosyltransferase 3A (UGT3A) enzymesIdentification of the human cytochromes P450 catalysing the rate-limiting pathways of gliclazide eliminationQuantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidationA phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferasesRenal drug metabolism in humans: the potential for drug-endobiotic interactions involving cytochrome P450 (CYP) and UDP-glucuronosyltransferase (UGT).Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies.Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities.Xenobiotic Metabolism in Mice Lacking the UDP-Glucuronosyltransferase 2 Family.Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearanceAldosterone glucuronidation by human liver and kidney microsomes and recombinant UDP-glucuronosyltransferases: inhibition by NSAIDs.Glucuronides from metabolites to medicines: a survey of the in vivo generation, chemical synthesis and properties of glucuronides.The role of drug metabolizing enzymes in clearance.Glucuronidation of drugs in humanized UDP-glucuronosyltransferase 1 mice: Similarity with glucuronidation in human liver microsomes.Massive naproxen overdose with serial serum levels.Cis-resveratrol glucuronidation kinetics in human and recombinant UGT1A sources.The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potentiaThe metabolism of trifluoperazine (TFP) exhibits atypical kinetic behavior in both human liver microsomes (HLMs) and monkey liver microsomes (MyLM).Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins.Natural Dietary Pigments: Potential Mediators against Hepatic Damage Induced by Over-The-Counter Non-Steroidal Anti-Inflammatory and Analgesic Drugs.Plasma and cerebrospinal fluid pharmacokinetics of naproxen in children.High body clearance and low oral bioavailability of alantolactone, isolated from Inula helenium, in rats: extensive hepatic metabolism and low stability in gastrointestinal fluids.A reappraisal of the 6-O-desmethylnaproxen-sulfating activity of the human cytosolic sulfotransferases.3D-QSAR studies on UDP-glucuronosyltransferase 2B7 substrates using the pharmacophore and VolSurf approaches.In Vitro Drug Metabolism Using Liver Microsomes.In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes.
P2860
Q24301940-DDE03609-7E67-4C53-9F62-6536A2BC1C15Q24336118-D916B6D7-3186-46CC-B09A-07A63C44CE3AQ24670563-B659EE4B-A278-4232-8FFF-90353B53EEACQ31034463-A1F12D6D-7FCE-4D13-88FA-AA2CDCE97F57Q33397528-3CDCBC0E-7063-43C9-BD4A-C9ECBC9901FEQ33714567-37D1C090-2942-4493-AD52-B20CC411CDA1Q34325249-FFB912B8-E876-43BC-8A4F-614B4A06D261Q34615173-1F8F9BC0-2DAF-4A66-8766-F2FDE5463519Q35187885-244C0B05-871F-49C9-9889-79FE74CD7510Q36316472-633956B0-C2D8-4CB9-AA22-7D5D807F333DQ36924729-BB059F6A-D771-4F7A-B0F4-A708F8E91E15Q37397801-E39702C2-A08B-4362-A4A7-DA0DC97BE9F5Q38104574-44078FFE-6380-417A-9FFB-2430AF6642AFQ38176051-CB38E19E-2115-4A0D-A1D3-C7596D719608Q41692521-B01CACBB-3794-418E-9511-FB5B1F419A43Q43200017-C6530C60-EEC8-449F-879A-320A7CA73F9FQ43217492-19DBB021-9FEF-4F33-A302-5EC03D194ADCQ43268650-CCEC41F7-F58E-4620-A1F0-93B103259024Q46955249-D3F0C889-3EF7-4A73-9D76-579E1592AB00Q47853973-64A54886-22EF-4F07-B4C4-788AEAB627A2Q48174531-A93FD9A5-B289-42FE-A670-BA04A5F851ABQ48216103-7FB00216-7EC7-4AE3-BF0E-62172DE00DF5Q48918037-FDF34E6C-7E0F-465D-8178-9ED47B4CE230Q51146807-02ABB390-E3A6-4B82-98B7-B2F782A9D09CQ51383600-8D5E0DC8-F42B-4BE1-8C9D-DE7012D9A0CDQ51499112-43D3EB9B-67D1-422F-931B-CBF6DCB8BBE5Q51643121-59ACC292-7387-4BF5-9D13-7D2E6CB63027
P2860
S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@ast
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@en
type
label
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@ast
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@en
prefLabel
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@ast
S-Naproxen and desmethylnaprox ...... n the elimination of naproxen.
@en
P2093
P2860
P1476
S-Naproxen and desmethylnaprox ...... in the elimination of naproxen
@en
P2093
David J Elliot
John O Miners
Kathleen M Knights
Kushari Bowalgaha
Stellan Swedmark
P2860
P304
P356
10.1111/J.1365-2125.2005.02446.X
P407
P577
2005-10-01T00:00:00Z